about
Application of a method used to deconstruct a single dose pharmacokinetic profile from multiple dose data.Statewide analysis of missed opportunities for human papillomavirus vaccination using vaccine registry data.Intrapartum magnesium sulfate and the potential for cardiopulmonary drug-drug interactions.Epidemiological Evaluation of Blood Culture Patterns among Neonates Receiving Vancomycinβ-D-glucan surveillance with preemptive anidulafungin for invasive candidiasis in intensive care unit patients: a randomized pilot studyIncorporating pharmacodynamic considerations into caffeine therapeutic drug monitoring in preterm neonates.Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4(+) T Cells from Aviremic Patients.Maternal magnesium sulphate exposure predicts neonatal magnesium blood concentrations.Characteristics and publication patterns of obstetric studies registered in ClinicalTrials.govEvolution of interventional vancomycin trials in light of new antibiotic development in the USA, 1999-2012.Optimal design in pediatric pharmacokinetic and pharmacodynamic clinical studies.Pharmacokinetic considerations in the use of antivirals in neonates.Breast-feeding, Leptin:Adiponectin Ratio, and Metabolic Dysfunction in Adolescents with Obesity.Pharmacodynamic studies of voriconazole: informing the clinical management of invasive fungal infections.AUC-Guided Vancomycin Dosing in Adolescent Patients With Suspected Sepsis.A propensity-matched cohort study of vancomycin-associated nephrotoxicity in neonates.Pediatric vancomycin dosing: Trends over time and the impact of therapeutic drug monitoring.The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder.Bias and variance evaluation of QT interval correction methods.Short forms of the "reference-" and "working-memory" Morris water maze for assessing age-related deficitsA new approach to the limiting dilution assayThe duration of measuring partial AUCs for the assessment of bioequivalenceEffect of clopidogrel on the steady-state pharmacokinetics of fluvastatin
P50
Q30909557-53B4D5EB-F2FB-4F6A-95F6-BF106DA33924Q31122475-30124176-3FF8-4D4D-A116-F7A45E4B5121Q33911412-0ACF37A6-5F27-430B-B086-E83D00F279C4Q34294765-350CD204-6856-47F1-A9C9-18C6FC1A70A4Q34374081-5F0B3647-C2F2-4265-8C6F-2201E37E7AD5Q36041863-44EC8C70-2388-4436-8F1E-1BD339D93B3DQ36076018-1B14B7A0-4D43-41B5-99A9-2141DC807AA3Q37629389-E9AB9BE9-A820-4E9B-981C-1AA19013EA75Q37638488-74E3924E-537F-48A5-9F8C-ACBE1E78352AQ38159001-502DD09E-D725-47D8-BBF1-56B3C8BC4E7AQ38315070-2672D66A-3EAB-49F9-8D6F-CB8DE3BA1AFDQ38624965-676F3A1E-7CC2-43FE-A139-3464AA5C7388Q38688495-1D940AC8-ADBD-4653-A3D6-A1CD893AE8E6Q38880522-A80E39C9-5037-472A-9718-B8D173412A37Q39690311-C8F6767C-A53E-4DDE-9B81-9BF2116C9D98Q40985166-2BBDA890-08F2-41CE-A94B-ABFBDBF6EB47Q41723791-CB285CCA-0CD1-439A-897B-B17FDB5FF428Q42599261-1FE364B3-B82A-498D-84C0-E2B394CB465AQ53038113-1C52E5DE-810E-405E-B48A-AA792A9E032AQ67597608-90F2D60C-3358-41B3-B1B8-EA251E6350DEQ72033720-86149794-7657-4D31-A901-863FE7BA0A64Q74487882-F6FCE30D-D45E-4B40-936F-C17B4E6CE357Q80177908-A105FE5A-6259-4CBE-98AE-C79CD65D850F
P50
description
Forscher
@de
chercheur
@fr
investigador
@es
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
研究者
@zh
name
Alfred H Balch
@ast
Alfred H Balch
@en
Alfred H Balch
@es
Alfred H Balch
@nl
type
label
Alfred H Balch
@ast
Alfred H Balch
@en
Alfred H Balch
@es
Alfred H Balch
@nl
prefLabel
Alfred H Balch
@ast
Alfred H Balch
@en
Alfred H Balch
@es
Alfred H Balch
@nl
P1153
7102863794
P21
P31
P496
0000-0002-2782-9885